DCT

1:25-cv-00926

BioDelivery Sciences Intl Inc v. Alvogen PB Research & Development LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-00926, D. Del., 07/24/2025
  • Venue Allegations: Venue is asserted based on Defendants' incorporation in Delaware, regular business conduct within the district, and consent to jurisdiction and venue in prior related litigation in the same court.
  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) for a generic version of the chronic pain drug BELBUCA® infringes a patent related to transmucosal drug delivery film technology.
  • Technical Context: The technology concerns a multi-layer, bioerodable film for delivering buprenorphine through the buccal mucosa (cheek lining) to provide steady-state pain relief while minimizing side effects.
  • Key Procedural History: This case follows a prior lawsuit ("the 1395 Action") between the same parties involving an earlier ANDA. In that case, the court found infringement of the patent-in-suit, a decision affirmed by the Federal Circuit, resulting in an injunction preventing the launch of the generic until 2032. The current complaint alleges Defendant made a "minor" modification to its product formulation and filed a new ANDA in an attempt to circumvent the prior judgment. This history places the doctrines of res judicata and collateral estoppel at the center of the dispute.

Case Timeline

Date Event
2011-12-21 '539 Patent Priority Date
2015-10-23 FDA approves NDA No. 207932 for BELBUCA
2018-02-27 U.S. Patent No. 9,901,539 Issues
2018-05-23 Alvogen submits original ANDA No. 211594
2018-09-07 Plaintiffs file prior lawsuit ("1395 Action")
2021-03-01 Bench trial commences in the 1395 Action
2021-12-20 Court issues opinion in 1395 Action finding infringement
2022-01-21 Final Judgment entered in 1395 Action
2022-12-21 Federal Circuit affirms Final Judgment in 1395 Action
2023-02-10 Federal Circuit mandate issues in 1395 Action
2025-02-14 Alvogen submits supplement to original ANDA
2025-03-04 Plaintiffs receive "Second Notice Letter" regarding the supplement
2025-03-21 FDA converts approval of ANDA 211594 to tentative
2025-04-09 Alvogen files new ANDA No. 220582 with modified formulation
2025-06-09 Plaintiffs receive "Third Notice Letter" regarding new ANDA
2025-07-24 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Patent No. 9,901,539, "Transmucosal Drug Delivery Devices for Use in Chronic Pain Relief," issued February 27, 2018.

U.S. Patent No. 9,901,539 - "Transmucosal Drug Delivery Devices for Use in Chronic Pain Relief"

The Invention Explained

  • Problem Addressed: The patent's background describes the difficulty of treating chronic pain, noting that oral delivery of opioids like buprenorphine is inefficient due to high "first-pass metabolism" in the liver, and that existing treatments can have significant adverse effects '539 Patent, col. 1:26-41 '539 Patent, col. 1:57-62
  • The Patented Solution: The invention is a transmucosal drug delivery device, specifically a bioerodable film, designed to adhere to the inside of the cheek. It features a two-layer system: a "mucoadhesive layer" containing a low dose of buprenorphine in a buffered environment (pH 4.0-6.0) to facilitate absorption, and a "backing layer" with a different pH (4.0-4.8) that acts as a barrier '539 Patent, col. 2:25-48 This backing layer creates a "unidirectional gradient," directing the drug toward the cheek lining for efficient uptake into the bloodstream and preventing it from being washed away by saliva, which would lead to ineffective swallowing '539 Patent, col. 2:30-37
  • Technical Importance: This design allows for the administration of low doses of buprenorphine to achieve therapeutic plasma concentrations for chronic pain management, while aiming to reduce common opioid side effects like constipation '539 Patent, col. 1:57-2:4 '539 Patent, col. 7:62-8:4

Key Claims at a Glance

  • The complaint asserts independent claims 1 and 9, as well as dependent claims 5 and 20 (' Compl. ¶72).
  • Independent Claim 1 is a method for treating chronic pain, requiring:
    • Administering a mucoadhesive bioerodable drug delivery device once or twice daily.
    • The device comprises a bioerodable mucoadhesive layer with 100 µg to 0.9 mg of buprenorphine, buffered to a pH between about 4.0 and 6.0.
    • The device also comprises a backing layer buffered to a pH between about 4.0 and 4.8 that does not contain an opioid antagonist.
    • The device provides a specified steady-state peak plasma concentration (Cmax) of buprenorphine.
    • The subject is "opioid-experienced."
    • The treatment results in "mild or moderate common opioid adverse effects, or no common opioid adverse effects."
  • Independent Claim 9 is a method for treating moderate to severe chronic low back pain, requiring:
    • Administering a similar two-layer device twice daily.
    • The mucoadhesive layer has an "effective amount" of buprenorphine in a buffered polymeric environment (pH 4-6).
    • The backing layer is buffered to a pH between about 4.0 and 4.8 and lacks an opioid antagonist.
    • The subject is "opioid-experienced" and experiences only mild, moderate, or no common opioid adverse effects.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Alvogen's generic buprenorphine buccal film products, for which it seeks FDA approval via Abbreviated New Drug Application (ANDA) No. 220582 ('Compl. ¶¶59-60).

Functionality and Market Context

  • The product is intended to be a generic equivalent of Plaintiff's BELBUCA® product for pain treatment ('Compl. ¶2; Compl. ¶60). The act of infringement alleged is the filing of the ANDA itself, which seeks approval to market the generic drug before the expiration of the '539 Patent ('Compl. ¶72).
  • The central technical feature discussed in the complaint is a modification from a previously litigated formulation. The new formulation involves the removal of "certain amounts of citric acid from the backing layer," which Alvogen allegedly stated results in an "increased pH for the inactive layer" ('Compl. ¶51). Despite this change, Alvogen has represented to the FDA that this is a "minor difference in formulation" and intends to rely on the bioequivalency studies from its prior, infringing ANDA submission ('Compl. ¶62; Compl. ¶64).
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed element-by-element infringement analysis for the modified product in ANDA No. 220582. Instead, it relies on broad allegations of infringement and the argument that the new product is not materially different from the product previously found to be infringing in the 1395 Action. The following chart summarizes the infringement theory for Claim 1 as can be constructed from the complaint's allegations.

U.S. Patent No. 9,901,539 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating chronic pain, the method comprising: administering to a subject in need thereof a mucoadhesive bioerodable drug delivery device, wherein the device is administered once or twice daily... The accused product is a buprenorphine buccal film, and the complaint alleges Alvogen intends for it to be prescribed and used by patients for pain treatment in an infringing manner. ¶60; ¶74 col. 2:11-15
wherein the device comprises: a bioerodable mucoadhesive layer comprising about 100 µg to about 0.9 mg buprenorphine and buffered to a pH of between about 4.0 and about 6.0; The accused product is a buprenorphine film offered in dosages from 75 µg to 900 µg. The complaint implies this layer is unchanged from the prior infringing product. ¶60; ¶72 col. 8:50-65
and a backing layer buffered to a pH of between about 4.0 and about 4.8 and that does not include an opioid antagonist; The complaint alleges Alvogen modified the backing layer by removing citric acid, resulting in an "increased pH." Plaintiff alleges this modified layer still infringes, while Defendant argues it does not. ¶51; ¶55; ¶72 col. 2:39-41
wherein the device provides a steady-state Cmax of plasma buprenorphine concentration in a range between about 0.156 and about 0.364 ng/mL; The complaint alleges Alvogen is relying on bioequivalency studies from its prior ANDA (No. 211594), which presumably demonstrated this pharmacokinetic profile. ¶52; ¶62 col. 15:49-55
wherein the subject is an opioid-experienced subject; and wherein the subject treated experiences mild or moderate common opioid adverse effects... The complaint alleges Alvogen's product, if approved, will be prescribed to patients, including those who are opioid-experienced, to practice the claimed methods. ¶74; ¶75 col. 7:12-29

Identified Points of Contention

  • Technical Question: The primary technical dispute centers on the modified backing layer. Does this layer, which has an "increased pH" from the removal of citric acid ('Compl. ¶51), still have a pH that falls "between about 4.0 and about 4.8" as required by the claim? The complaint does not provide the new pH value, making this a central question of fact.
  • Scope Question: The construction of the term "about" in the phrase "about 4.8" will be critical. The court will need to determine how much deviation from 4.8 is permissible before the backing layer is no longer within the claim's scope, especially given the patent's emphasis on pH control.
  • Legal Question: A threshold issue is procedural. Do the legal doctrines of res judicata or collateral estoppel, stemming from the final judgment in the 1395 Action, prevent Alvogen from arguing that its modified product is non-infringing, particularly since it allegedly characterized the change as "minor" to the FDA ('Compl. ¶64; Compl. Count IV)?

V. Key Claim Terms for Construction

  • The Term: "buffered to a pH of between about 4.0 and about 4.8"
  • Context and Importance: This term, defining the pH of the backing layer, is the focal point of the technical dispute. Alvogen modified its formulation by removing citric acid, thereby increasing the pH of this layer, and now asserts non-infringement on this basis ('Compl. ¶51; Compl. ¶55). The interpretation of this range, particularly the word "about," will be decisive for the infringement analysis.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party arguing for a broader scope may point to the patent's use of "about" as an explicit signal that the endpoints are not absolute. The specification does not provide an explicit definition for "about," which could open the door to a standard construction that allows for minor, insubstantial variations.
    • Evidence for a Narrower Interpretation: A party seeking a narrower scope may argue that the patent deliberately specifies a distinct and tighter pH range for the backing layer (4.0-4.8) compared to the mucoadhesive layer (4.0-6.0), suggesting the upper limit of 4.8 is a meaningful technical parameter '539 Patent, col. 2:25-48 The complaint also notes that in the prior litigation, the court found that the "pH of the backing layer affects the bioavailability of the product," which could be used to argue that the claimed range is critical to the invention's function and should not be expanded to cover a formulation that intentionally removes a buffering agent ('Compl. ¶114).

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. It claims Alvogen will induce infringement by providing instructions and labels that will inevitably lead physicians and patients to use the generic film in a manner that practices the patented methods ('Compl. ¶74). It further alleges contributory infringement by asserting that Alvogen's film is a material part of the invention, is not a staple article of commerce suitable for substantial non-infringing use, and is being sold with knowledge that it will be used to infringe ('Compl. ¶75).
  • Willful Infringement: The complaint alleges that Alvogen has knowledge of the '539 patent from extensive prior litigation and that it filed the new ANDA specifically "to circumvent the Court's Final Judgment in the 1395 Action" ('Compl. ¶73). It also pleads that the case is "exceptional" under 35 U.S.C. § 285, seeking enhanced damages and attorney's fees based on Alvogen's alleged litigation conduct and contradictory positions before the court and the FDA ('Compl. ¶112; Compl. ¶117). The basis for this allegation is pre-suit knowledge.

VII. Analyst's Conclusion: Key Questions for the Case

  1. A question of preclusion: Does the doctrine of res judicata or collateral estoppel, arising from the prior judgment against Alvogen's nearly identical product, bar Alvogen from now arguing that a "minor" formulation change allows it to escape infringement?
  2. A question of technical scope: If the preclusion argument fails, does the modified backing layer in Alvogen's new generic product, with its "increased pH," factually fall within the claimed range of "between about 4.0 and about 4.8"? This will depend on both the evidence of the product's actual pH and the court's construction of the term "about."
  3. A question of litigation conduct: Do Alvogen's actions-re-litigating a patent it already lost on after making a minimal change, while simultaneously representing to the FDA that the change is therapeutically insignificant-rise to the level of conduct that would make this an "exceptional" case warranting an award of attorney's fees?
Loading Complaint